Activities of two metalloproteinases: MMP-2 and MMP-9 were studied in the primary (WM793, WM115) and metastatic (Lu1205, WM266-4) melanoma cell lines after 24-h and 48-h treatment with protein kinase inhibitors and their combinations (Fig. 4). This evidence concerns the gene MMP9 and melanoma.